Trial Profile

Phase I Dose-Escalation Study to Determine the Safety and Tolerability of an Intratumoural Injection of EBC-46

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tigilanol tiglate (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Sponsors QBiotics

Most Recent Events

31 May 2023 According to a QBiotics Group Limited media release, the safety and efficacy data from this study will be presented at the Sachs 9th Annual Immuno-Oncology Innovation Forum and the BIO International Convention, both being held in the US through June 2023, by Richard Godfrey.
12 Aug 2020 Results published in the QBiotics Media Release
09 Dec 2019 According to a QBiotics media release, results from this trial have been published in the journal EBioMedicine (a peer-reviewed research journal by The Lancet.)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com